AU Patent

AU2015237243A1 — Progesterone formulations

Assigned to TherapeuticsMD Inc · Expires 2016-09-29 · 10y expired

What this patent protects

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters, in particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in nee…

USPTO Abstract

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters, in particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015237243A1
Jurisdiction
AU
Classification
—
Expires
2016-09-29
Drug substance claim
No
Drug product claim
No
Assignee
TherapeuticsMD Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.